

Ear, Nose and Throat Cancers



Coordinator

Quer Agustí, Miquel
mquer@santpau.cat

FGS

Members

De Juan Beltran, Julia	FGS
García Lorenzo, Jacinto	FGS
Gras Cabrerizo, Juan Ramon	FGS
Kolanczak, Katarzyna Alicia	FGS
Leon Vintró, Xavier	FGS
López Vilas, Montserrat	FGS
Montserrat Gili, Joan Ramon	FGS
Orus Dotu, Cesar	FGS
Pujol Olmo, Albert	FGS
Venegas Pizarro, Maria del Prado	FGS

Main Lines of Research

- ▶ Genetic and molecular predictors of response to head and neck cancer (with the Oncogenesis and Antitumour Drugs group).
- ▶ Molecular mechanisms of inflammation in head and neck cancer (with the Inflammation Laboratory).
- ▶ Nasosinal endoscopic surgery: innovations in skull base techniques.
- ▶ Internal ear: aspects related to severe deafness, cochlear implants and otoneurological surgery of tumours.

Challenges

- ▶ Promote clinical and translational research into head and neck cancer with a very large database of head and neck cancers.
- ▶ Study relevant clinical issues in depth (second-third neoplasms, staging concerns, prognostic factors, etc) and investigate translational aspects such as genetic and molecular predictors.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Angiology, Vascular Biology and Inflammation (Dr. Lluís Vila).
- ▶ Oncogenesis and Antitumour Drugs (Dr. Ramon Mangues).
- ▶ Translational Molecular Oncology (Dr. Matilde Parreño).

External Collaborations

- ▶ Catalan Institute of Oncology: Epidemiology (Dr. X. Bosch).
- ▶ Catalan Institute of Oncology: Oncology (Dr. Ricard Mesia).
- ▶ Hospital Joan XXIII: Head and Neck Cancer (Dr. F.J. Avilés).
- ▶ Hospital Central de Asturias: Head and Neck Cancer (Dr. C. Suárez).

Active Grants

- ▶ Xavier Leon Vintró. Herramienta de predicción de respuesta a la radioterapia basada en la expresión de genes relacionados con la transición epitelial-mesenquimal en cáncer de cabeza y cuello. PI14/01918. Instituto de Salud Carlos III. Duration: 2015-2018. 71,500.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2017

- ▶ Miquel Quer Agustí. Émbolos tumorales circulantes hCXCR4/SerpinE1 en el pronóstico del cáncer de cabeza y cuello. PI17/00584. Instituto de Salud Carlos III. Duration: 2018-2020. 2,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

Theses

- ▶ Ricard Simó. Intrathoracic goitres: comparative study of the transcervical approach versus the combined cervicothoracic. Universitat Autònoma de Barcelona. Directors: Miquel Quer and Xavier León. Date of defense: 11/05/2017.
- ▶ Jose Miguel Costa González. Impacto del carcinoma de cabeza y cuello en la actividad laboral de los pacientes. Universitat Autònoma de Barcelona. Directors: Miquel Quer, Xavier León and Montserrat López. Date of defense: 17/02/2017.

*TIF: 44.781 **MIF: 2.6364

Aviles-Jurado F.X., Flores J.C., Guma J., Cepe-ruelo-Mallafre V., Casanova-Marques R., Gomez D., Vendrell J.J., Leon X., Vilaseca I., Terra X., Prognostic relevance of insulin resistance on disease-free survival in head and neck squamous cell carcinomas: Preliminary results (2017) HEAD NECK-J SCI SPEC, 39 (12), 2501-2511.

IF: 2.471

Codina Aroca A., Gras Cabrerizo J.R., De Juan Delago M., Massegur Solench H., Spontaneous cerebrospinal fluid fistula in the clivus (2017) EUR ANN OTORHINOLARY, 134 (6), 431-434.

IF: 1.036

Garcia J., Lopez M., Lopez L., Bague S., Granell E., Quer M., Leon X., Validation of the pathological classification of lymph node metastasis for head and neck tumors according to the 8th edition of the TNM Classification of Malignant Tumors (2017) ORAL ONCOL, 70, 29-33.

IF: 4.636

Garcia Lorenzo J., Montoro Martinez V., Rigo Quera A., Codina Aroca A., Lopez Vilas M., Quer Agusti M., Leon Vintro X., Modifications in the treatment of advanced laryngeal cancer throughout the last 30 years (2017) EUR ARCH OTO-RHINO-L, 274 (9), 3449-3455.

IF: 1.546

Garcia-Lorenzo J., Farre N., Codina A., Gallego O., de Vega M., Leon X., Nasopharyngeal carcinoma: 30-year experience of a single institution in a non-endemic area (2017) CLIN TRANSL ONCOL, 19 (6), 777-783.

IF: 2.392

Lenarz T., Muller L., Czerniejewska-Wolska H., Valles Varela H., Orus Dotu C., Durko M., Huarte Irujo A., Piszcztowski B., Zadroziak M., Irwin C., Graham P.L., Wyss J., Patient-Related Benefits for Adults with Cochlear Implantation: A Multicultural Longitudinal Observational Study (2017) AUDIOL NEURO-OTOL, 22 (2), 61-73.

IF: 2.078

Leon X., Valero C., Rovira C., Rodriguez C., Lopez M., Garcia-Lorenzo J., Quer M., Relationship between response to induction chemotherapy and disease control in patients with advanced laryngeal carcinoma included in an organ preservation protocol (2017) EUR ARCH OTO-RHINO-L, 274 (6), 2581-2587.

IF: 1.546

Leon X., Rigo A., Farre N., Lopez M., Garcia J., de Juan J., Quer M., Prognostic significance of extracapsular spread in isolated neck recurrences in head and neck squamous cell carcinoma patients (2017) EUR ARCH OTO-RHINO-L, 274 (1), 527-533.

IF: 1.546

Lopez F., Williams M.D., Skalova A., Hellquist H., Suarez C., Nixon I.J., Rodrigo J.P., Cardesa A., Strojan P., Quer M., Hunt J.L., Rinaldo A., Ferlito A., How Phenotype Guides Management of the Most Common Malignant Salivary Neoplasms of the Larynx? (2017) ADV THER, 34 (4), 813-825.

IF: 3.085

Lopez F., Williams M.D., Cardesa A., Hunt J.L., Strojan P., Rinaldo A., Nixon I.J., Rodrigo J.P., Saba N.F., Mendenhall W.M., Quer M., Suarez C., Ferlito A., How phenotype guides management of non-conventional squamous cell carcinomas of the larynx? (2017) EUR ARCH OTO-RHINO-L, 274 (7), 2709-2726.

IF: 1.546

Martel M., Alemany L., Taberna M., Mena M., Tous S., Bague S., Castellsague X., Quer M., Leon X., The role of HPV on the risk of second primary neoplasia in patients with oropharyngeal carcinoma (2017) ORAL ONCOL, 64, 37-43.

IF: 4.636

Olsen K.D., Quer M., de Bree R., Vander Poorten V., Rinaldo A., Ferlito A., Deep lobe parotidectomy—why, when, and how? (2017) EUR ARCH OTO-RHINO-L, 274 (12), 4073-4078.

IF: 1.546

Pardo L., Valero C., Lopez M., Garcia J., Camacho M., Quer M., Leon X., The prognostic value of pretreatment platelet count in patients with head and neck squamous cell carcinoma (2017) AURIS NASUS LARYNX, 44 (3), 313-318.

IF: 1.387

Quer M., Vander Poorten V., Takes R.P., Silver C.E., Boedeker C.C., de Bree R., Rinaldo A., Sanabria A., Shah A.R., Pujol A., Zbaren P., Ferlito A., Surgical options in benign parotid tumors: a proposal for classification (2017) EUR ARCH OTO-RHINO-L, 274 (11), 3825-3836.

IF: 1.546

Rodrigo J.P., Villaronga M.A., Menendez S.T., Hermida-Prado F., Quer M., Vilaseca I., Allanca E., Pedregal Mallo D., Astudillo A., Garcia-Pedrero J.M., A Novel Role for Nanog As An Early Cancer Risk Marker in Patients with Laryngeal Precancerous Lesions (2017) SCI REP-UK, 7 (1).

IF: 4.122

Schroeder L., Boscolo-Rizzo P., Dal Cin E., Romeo S., Baboci L., Dyckhoff G., Hess J., Lucena-Porcel C., Byl A., Becker N., Alemany L., Castellsague X., Quer M., Leon X., Wiesenfarth M., Pawlita M., Holzinger D., Human papillomavirus as prognostic marker with rising prevalence in neck squamous cell carcinoma of unknown primary: A retrospective multicentre study (2017) EUR J CANCER, 74, 73-81.

IF: 7.191

Valero C., Pardo L., Lopez M., Garcia J., Camacho M., Quer M., Leon X., Pretreatment count of peripheral neutrophils, monocytes, and lymphocytes as independent prognostic factor in patients with head and neck cancer (2017) HEAD NECK-J SCI SPEC, 39 (2), 219-226.

IF: 2.471